4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Current Assets data on file, last reported at $405.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $405.4 million, up 21.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $405.4 million (up 21.89% YoY), and the FY2025 annual result was $413.1 million, down 5.01% from the prior year.
• Current Assets declined to $405.4 million in Q1 2026 per FDMT's latest filing, from $413.1 million in the prior quarter.
• Over five years, Current Assets peaked at $552.6 million in Q2 2024 and troughed at $207.0 million in Q1 2023.
• A 5-year average of $346.6 million and a median of $317.8 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets surged 158.69% in 2024, then sank 45.12% in 2025.
• A 5-year view of Current Assets shows it stood at $220.5 million in 2022, then soared by 34.5% to $296.6 million in 2023, then soared by 46.65% to $434.9 million in 2024, then fell by 5.01% to $413.1 million in 2025, then retreated by 1.88% to $405.4 million in 2026.
• Business Quant data shows FDMT's Current Assets at $405.4 million in Q1 2026, $413.1 million in Q4 2025, and $312.4 million in Q3 2025.